Clinical Guide · 2026
What your standard lipid panel misses — and the markers that actually predict heart disease.
TL;DR — The Quick Answer
For accurate cardiovascular risk assessment in 2026, a standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) is insufficient as a standalone tool. ApoB (apolipoprotein B) is now recognized by leading cardiology societies as the superior measure of atherogenic particle burden. Lp(a) — a genetically determined lipoprotein — is an independent risk factor affecting approximately 20% of the population and is missed entirely by standard panels. Sorrell MD evaluates ApoB, Lp(a), hs-CRP, homocysteine, and imaging correlates to build a complete cardiovascular risk picture.
ApoB measures the total count of atherogenic particles (LDL, VLDL, IDL, Lp(a)) — one molecule per particle. It's a superior predictor of cardiovascular events compared to LDL-C and is recommended by the European Society of Cardiology and the Canadian Cardiovascular Society as the primary lipid treatment target. Yet most routine panels still don't include it.
Lipoprotein(a) is a genetically determined lipoprotein that confers significant independent cardiovascular risk at elevated levels. It affects approximately 1 in 5 people, is not modifiable by lifestyle changes or most statins, and needs to be measured at least once in every adult. Standard panels omit it completely — yet elevated Lp(a) is the leading genetic cause of premature heart disease.
hs-CRP (high-sensitivity C-reactive protein) reflects vascular inflammation — a key independent driver of atherosclerosis even in people with normal LDL. Homocysteine elevation is an independent risk factor for thrombosis and cardiovascular disease, and is often caused by B12/folate deficiency — a modifiable, inexpensive fix that standard panels miss.
We offer two imaging approaches depending on clinical context. A coronary artery calcium (CAC) score is a low-radiation CT that detects calcified (hard) plaque and powerfully reclassifies intermediate-risk patients — a score of 0 dramatically lowers event probability, while a high score prompts aggressive prevention. However, CAC only sees hard plaque and misses soft (non-calcified) plaque, which can be equally dangerous. For a more complete picture, coronary CT angiography (CTA) visualizes both hard and soft plaque, identifies stenosis, and characterizes plaque composition. We recommend CTA when CAC alone may underestimate risk — particularly in younger patients or those with high suspicion despite a low CAC score.
Beyond basic LDL-C, advanced lipid testing (NMR LipoProfile) reveals lipoprotein particle number and size — distinguishing truly dangerous atherogenic patterns (small, dense LDL) from less harmful phenotypes. This helps avoid over-treating benign lipid elevations and identify undertreated risk in patients with apparently "normal" cholesterol.
| Marker / Assessment | Standard Lipid Panel | Advanced CVD Assessment (Sorrell MD) |
|---|---|---|
| ApoB | Not included | Measured |
| Lp(a) | Not included | Measured (lifetime risk marker) |
| LDL particle number & size | Not included | NMR LipoProfile available |
| Inflammatory markers | Not included | hs-CRP, homocysteine, Lp-PLA2 |
| Imaging | Not ordered | CAC score (hard plaque) and/or CTA (hard + soft plaque) |
| Risk synthesis | Framingham risk score only | Multi-marker + imaging risk integration |
What is ApoB and why is it better than LDL-C?
ApoB (apolipoprotein B) is a protein that wraps around every atherogenic lipoprotein particle — exactly one ApoB per particle. LDL-C measures the cholesterol content inside LDL particles, but doesn't tell you how many particles are carrying that cholesterol. Two people can have identical LDL-C levels but very different ApoB levels — and very different cardiovascular risk. Since it's particles that embed in arterial walls (not cholesterol itself), particle count predicts risk more accurately. The 2021 European Cardiovascular Society guidelines now recommend ApoB as the primary lipid treatment target.
What is Lp(a) and why does it matter?
Lipoprotein(a) — or Lp(a) — is a modified form of LDL with an additional protein called apolipoprotein(a) that makes it both highly atherogenic (promotes plaque buildup) and thrombogenic (increases clotting risk) simultaneously. Lp(a) levels are 80–90% genetically determined — lifestyle changes and most statins don't significantly lower them. Elevated Lp(a) above 50 mg/dL or 125 nmol/L confers 2–3x increased cardiovascular risk and is the leading genetic cause of premature heart disease. About 20% of the global population has elevated Lp(a). New targeted RNA-based therapies in trials can lower it by over 80%.
What's the difference between a CAC score and a CTA?
A coronary artery calcium (CAC) score uses a low-radiation CT to detect calcified (hard) plaque in the coronary arteries. It's excellent for reclassifying intermediate-risk patients — a score of 0 dramatically lowers event probability, while a high score (300+ Agatston units) prompts aggressive prevention. However, CAC only detects hard plaque and completely misses soft (non-calcified) plaque, which can be unstable and equally dangerous. A coronary CT angiography (CTA) provides a more complete picture by visualizing both hard and soft plaque, identifying stenosis, and characterizing plaque composition. We may recommend CTA when soft plaque is suspected — particularly in younger patients, those with elevated Lp(a), or when CAC is low but clinical suspicion remains high.
What does hs-CRP tell me about my heart risk?
hs-CRP (high-sensitivity C-reactive protein) is a marker of systemic inflammation. In the cardiovascular context, elevated hs-CRP (above 2 mg/L) reflects ongoing vascular inflammation that accelerates atherosclerosis independent of cholesterol levels. The landmark JUPITER trial showed that people with normal LDL-C but elevated hs-CRP derived significant benefit from statin therapy. hs-CRP also motivates lifestyle interventions — it responds to anti-inflammatory diet, weight loss, and aerobic exercise, making it a useful motivational and monitoring tool.
How is homocysteine related to cardiovascular risk?
Homocysteine is an amino acid that, at elevated levels (above 10–15 μmol/L), damages arterial endothelium and promotes clot formation. Elevated homocysteine is an independent risk factor for cardiovascular disease, stroke, and dementia. The most common cause is deficiency in B12, folate, and B6 — which is nutritionally modifiable. Testing homocysteine is valuable because the treatment (targeted B-vitamin supplementation) is safe, inexpensive, and effective, yet it's completely omitted from standard cardiovascular panels.
How is this different from a standard annual physical?
A standard annual physical includes a basic lipid panel, blood pressure, blood sugar, and weight, then applies a Framingham or ASCVD 10-year risk calculator. This misses ApoB, Lp(a), particle size, inflammatory markers, and imaging — all of which substantially refine risk estimates and change treatment decisions. For a 45-year-old with a family history of early heart disease and "normal" cholesterol, only an advanced assessment reveals whether early atherosclerosis is actually present.
Does Sorrell MD coordinate with imaging centers for CAC and CTA?
Yes. Dr. Sorrell can order a CAC score or coronary CTA — or help interpret one you've already had — integrating the findings into a comprehensive risk assessment and action plan. Lab panels are ordered through national networks (Quest, LabCorp) with draw sites near you — all coordinated via telemedicine.
Book a free discovery call to review your cardiovascular history and find out what your current labs are — and aren't — telling you.
Book a Free Call